keyword
MENU ▼
Read by QxMD icon Read
search

Chronic idiopathic urticaria

keyword
https://www.readbyqxmd.com/read/28511822/posttraumatic-stress-disorder-ptsd-and-the-dermatology-patient
#1
Madhulika A Gupta, Patricia Jarosz, Aditya K Gupta
Dermatologic symptoms can be associated with posttraumatic stress disorder (PTSD) in several situations: (1) as features of some core PTSD symptoms, such as intrusion symptoms manifesting as cutaneous sensory flashbacks, as autonomic arousal manifesting as night sweats and idiopathic urticaria, and as dissociation manifesting as numbness and dermatitis artefacta; (2) the cutaneous psychosomatic effects of emotional and physical neglect and sexual abuse (eg, infantile eczema, cutaneous self-injury, and body-focused repetitive behaviors such as trichotillomania and skin picking disorder) and eating disorders, which can have dermatologic effects; (3) the direct effect of physical or sexual abuse or catastrophic life events (eg, earthquakes) on the skin; and (4) as a result of significant alterations in hypothalamic-pituitary-adrenal and sympatho-adrenal medullary axes, which can affect neuroendocrine and immune functions, and can lead to exacerbations of stress-reactive inflammatory dermatoses such as psoriasis, chronic urticaria, and atopic dermatitis...
May 2017: Clinics in Dermatology
https://www.readbyqxmd.com/read/28452298/corticosteroid-related-toxicity-in-patients-with-chronic-idiopathic-urticaria-chronic-spontaneous-urticaria
#2
Dennis Ledford, Michael S Broder, Evgeniya Antonova, Theodore A Omachi, Eunice Chang, Allan Luskin
BACKGROUND: Treatments for patients with chronic idiopathic urticaria (CIU)-chronic spontaneous urticaria (CSU) who were unresponsive to antihistamines include oral corticosteroids (OCS). Risks of OCS-related side effects in these patients have not been described quantitatively. OBJECTIVE: To investigate the relationship between OCS use and the risk of developing side effects possibly attributable to OCS and associated health care costs in privately insured patients with CIU/CSU...
November 1, 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28452145/how-to-manage-chronic-urticaria-beyond-guidelines-a-practical-algorithm
#3
Krzysztof Rutkowski, Clive E H Grattan
Chronic urticaria (CU) is a disease characterised by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders...
April 28, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28390587/clinical-features-of-adolescents-with-chronic-idiopathic-or-spontaneous-urticaria-review-of-omalizumab-clinical-trials
#4
Stanley Goldstein, Susan Gabriel, Farid Kianifard, Benjamin Ortiz, David P Skoner
BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups...
April 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28366435/efficacy-and-safety-of-omalizumab-in-japanese-and-korean-patients-with-refractory-chronic-spontaneous-urticaria
#5
Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami, Jooyoung Roh, Jae-Hyun Lee, Yuko Chinuki, Sang Woong Youn, Soo-Keol Lee, Naoko Inomata, Jeong-Hee Choi, Atsushi Fukunaga, Junyi Wang, Soichiro Matsushima, Steve Greenberg, Sam Khalil
BACKGROUND: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU...
March 21, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28302451/chronic-idiopathic-urticaria-systemic-complaints-and-their-relationship-with-disease-and-immune-measures
#6
Judy C Doong, Kris Chichester, Eric T Oliver, Lawrence B Schwartz, Sarbjit S Saini
BACKGROUND: Patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria sometimes report systemic complaints (SCs). OBJECTIVE: We sought to determine the frequency and characteristics of SCs among patients with CIU, as well as the association of SCs with disease measures, basophil histamine release, and serum tryptase. METHODS: Adult patients with CIU were recruited from a university allergy clinic. Patients completed a disease symptom survey and underwent blood sampling for subsequent basophil histamine release and serum tryptase measurement...
March 13, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28299827/factors-linked-to-disease-severity-and-time-to-remission-in-patients-with-chronic-spontaneous-urticaria
#7
REVIEW
Mario Sánchez-Borges, Fernan Caballero-Fonseca, Arnaldo Capriles-Hulett, Luis González-Aveledo, Marcus Maurer
BACKGROUND: Biomarkers useful for the evaluation and management of patients with chronic spontaneous urticaria (CSU) are not currently available. OBJECTIVE: A review of various clinical and laboratory markers that have been studied to assess their value for determining the severity or predicting the evolution of disease in adult patients with CSU. METHODS: A search of the medical literature on Pubmed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, chronic spontaneous urticaria, severity, prognosis, and treatment...
March 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28295198/analysis-of-disease-activity-categories-in-chronic-spontaneous-idiopathic-urticaria
#8
D Stull, D McBride, H Tian, A Gimenez Arnau, M Maurer, A Marsland, M-M Balp, S Khalil, C Grattan
BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score-here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD )-measures severity from 0 to 42. Insufficient evidence exists whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVE: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact...
March 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28226418/omalizumab-for-the-treatment-of-chronic-idiopathic-urticaria-systematic-review-of-the-literature
#9
REVIEW
Alessandro Tonacci, Lucia Billeci, Giovanni Pioggia, Michele Navarra, Sebastiano Gangemi
Omalizumab is recombinant humanized monoclonal antibody to immunoglobulin E. Guidelines for the treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) recommend the use of omalizumab as third-line therapy in addition to high doses of histamine receptor type 1 (H1 ) antihistamines when they are unsuccessful as first- and second-line therapy. We performed a systematic review of the literature to identify studies that evaluated the efficacy of omalizumab for the treatment of chronic idiopathic urticaria, in both controlled and real-world settings, to assess its potential role as a preferred therapy...
April 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28219063/elevated-nitrosative-stress-in-children-with-chronic-spontaneous-urticaria
#10
Fatih Dilek, Deniz Ozceker, Emin Ozkaya, Eray Metin Guler, Mebrure Yazici, Zeynep Tamay, Abdurrahim Kocyigit, Nermin Guler
BACKGROUND: Chronic spontaneous urticaria (CSU) is an idiopathic condition that seriously affects quality of life. It is well known that oxidative stress and nitrosative stress (NS) are generally involved in many chronic inflammatory diseases. This study aimed to evaluate the possible role of NS in the pathogenesis of CSU. METHODS: Thirty-two children with CSU and 22 healthy control subjects were enrolled in the study. Demographic and clinical features were defined, and disease activity was quantified using the urticaria activity score (UAS)...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28193678/aspirin-desensitization-in-patients-with-coronary-artery-disease-results-of-the-multicenter-adapted-registry-aspirin-desensitization-in-patients-with-coronary-artery-disease
#11
Roberta Rossini, Annamaria Iorio, Roberto Pozzi, Matteo Bianco, Giuseppe Musumeci, Sergio Leonardi, Corrado Lettieri, Irene Bossi, Paola Colombo, Stefano Rigattieri, Cinzia Dossena, Angelo Anzuini, Davide Capodanno, Michele Senni, Dominick J Angiolillo
BACKGROUND: There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease. The aim of the present study was to assess the safety and efficacy of a standard rapid desensitization protocol in patients with ASA sensitivity undergoing coronary angiography. METHODS AND RESULTS: This is a prospective, multicenter, observational study including 7 Italian centers including patients with a history of ASA sensitivity undergoing coronary angiography with intent to undergo percutaneous coronary intervention...
February 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28094164/disorders-characterized-by-predominant-or-exclusive-dermal-inflammation
#12
Mark R Wick
Some cutaneous inflammatory disorders are typified by a predominant or exclusive localization in the dermis. They can be further subdivided by the principal cell types into lymphocytic, neutrophilic, and eosinophilic infiltrates, and mixtures of them are also seen in a proportion of cases. This review considers such conditions. Included among the lymphoid lesions are viral exanthems, pigmented purpuras, gyrate erythemas, polymorphous light eruption, lupus tumidus, and cutaneous lymphoid hyperplasia. Neutrophilic infiltrates are represented by infections, Sweet syndrome, pyoderma gangrenosum, and hidradenitis suppurativa, as well as a group of so-called "autoinflammatory" dermatitides comprising polymorphonuclear leukocytes...
December 14, 2016: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/27971869/assure-csu-resource-use-and-economic-burden-in-patients-with-refractory-chronic-spontaneous-idiopathic-urticaria-in-italy
#13
A Roccia, L Rigoni, M R Cawson, D McBride, G W Canonica, M Balp
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971645/comparative-analysis-of-indirect-costs-associated-with-chronic-spontaneous-idiopathic-urticaria-results-from-the-assure-csu-study-in-7-countries
#14
D McBride, M Abuzakouk, M Balp, F Berard, G W Canonica, A Gimenez-Arnau, C Grattan, K Hollis, S Khalil, A Knulst, J Lacour, C Lynde, A Marsland, M Maurer, A Nakonechna, F J Ortiz de Frutoz, J Oude Elberink, C Proctor, G Sussman, K Weller
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971634/assessing-health-utility-values-for-chronic-spontaneous-idiopathic-urticaria-in-real-world-using-the-eq-5d-results-from-assure-csu-study
#15
K Hollis, M Abuzakouk, M Balp, F Berard, G W Canonica, A Gimenez-Arnau, C Grattan, S Khalil, A C Knulst, J Lacour, C Lynde, M Maurer, D McBride, A Nakonechna, F J Ortiz de Frutoz, J Oude Elberink, C Proctor, G Sussman, C Sweeney, H Tian, K Weller, A Marsland
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971603/comparison-of-direct-healthcare-costs-associated-with-chronic-spontaneous-idiopathic-urticaria-in-7-countries-results-from-the-assure-csu-study
#16
M Balp, M Abuzakouk, F Berard, G W Canonica, A Gimenez-Arnau, K Hollis, S Khalil, A Knulst, J Lacour, C Lynde, A Marsland, M Maurer, D McBride, A Nakonechna, F J Ortiz de Frutoz, J Oude Elberink, C Proctor, G Sussman, K Weller, C Grattan
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27957325/immunogenicity-of-a-peptide-based-anti-ige-conjugate-vaccine-in-non-human-primates
#17
Risini D Weeratna, Ghania Chikh, Lu Zhang, James D Fraser, Jennifer M Thorn, James R Merson, Michael J McCluskie, Brian R Champion, Heather L Davis
The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Cϵ3) of free human IgE in the blood and interstitial fluid. Although efficacious, use of omalizumab is limited due to restrictions on patient weight and pre-existing IgE levels, and frequent dosing (q2-4 weeks). A vaccine inducing anti-IgE antibodies has the potential for similar clinical benefits with less frequent dosing and relatively lower cost of goods...
June 2016: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/27939380/effect-of-omalizumab-on-blood-basophil-counts-in-patients-with-chronic-idiopathic-spontaneous-urticaria
#18
Sarbjit S Saini, Theodore A Omachi, Benjamin Trzaskoma, Henry N Hulter, Karin Rosén, Patricia M Sterba, Jean-Paul Courneya, Alan Lackey, Hubert Chen
No abstract text is available yet for this article.
December 6, 2016: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/27931301/corticosteroid-related-toxicity-in-patients-with-chronic-idiopathic-urticariachronic-spontaneous-urticaria
#19
Dennis Ledford, Michael S Broder, Evgeniya Antonova, Theodore A Omachi, Eunice Chang, Allan Luskin
BACKGROUND: Treatments for patients with chronic idiopathic urticaria (CIU)chronic spontaneous urticaria (CSU) who were unresponsive to antihistamines include oral corticosteroids (OCS). Risks of OCS-related side effects in these patients have not been described quantitatively. OBJECTIVE: To investigate the relationship between OCS use and the risk of developing side effects possibly attributable to OCS and associated health care costs in privately insured patients with CIU/CSU...
November 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/27911016/positive-impact-of-omalizumab-on-angioedema-and-quality-of-life-in-patients-with-refractory-chronic-idiopathic-spontaneous-urticaria-analyses-according-to-the-presence-or-absence-of-angioedema
#20
M Maurer, H Sofen, B Ortiz, F Kianifard, S Gabriel, J A Bernstein
BACKGROUND: Approximately 50% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report hives and angioedema; some experience hives/angioedema only. OBJECTIVE: Assess omalizumab's effect on angioedema and quality of life (QoL) in subgroups with refractory CIU/CSU: those with and without angioedema. METHODS: Patients received omalizumab (75, 150 or 300 mg) or placebo every 4 weeks for 12/24 weeks. Angioedema and QoL were assessed [Urticaria Patient Daily Diary and Dermatology Quality of Life Index (DLQI)]...
December 2, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
12612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"